Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell save search
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
VIRX | $0.9362 30.97% 21.62% 190K
|
Manufacturing
|
| O: -12.71%
H: 0.97%
C: -24.27%
t-cell positive topline trial therapeutics results
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market to Showcase Significant Growth at a CAGR of 15% by 2032 | DelveInsight
Published: 2024-04-15 (Crawled : 22:00) - prnewswire.com
INCY | $52.72 -0.94% -0.91% 2.1M
|
Health Technology
|
| O: -0.17%
H: 1.41%
C: -0.22%
t-cell for therapy growth market
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.0354 -0.83% -20.84% 34K
|
Communications
|
| O: -100.0%
H: NaN%
C: Infinity%
GILD | $66.93 -0.57% -0.55% 3.8M
|
Health Technology
|
| O: 0.5%
H: 0.83%
C: 0.28%
CTXR | $0.8162 8.86% 9.33% 640K
|
Health Technology
|
| O: 2.33%
H: 2.28%
C: -4.23%
hope treatment pharmaceuticals city for car-t trial
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
Published: 2024-04-09 (Crawled : 21:00) - globenewswire.com
INAB | $1.0 2.01% 3.89% 170K
|
|
| O: 6.42%
H: 1.72%
C: -5.17%
cell preclinical for therapy platform
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
Published: 2024-04-07 (Crawled : 00:00) - globenewswire.com
ITOS | $10.68 -3.78% -3.93% 200K
|
Health Technology
|
| O: -1.0%
H: 2.26%
C: -1.29%
eos-984 association cancer cell research preclinical for meeting
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
Published: 2024-04-05 (Crawled : 21:00) - globenewswire.com
ELTX | $9.3 -3.43% -5.82% 41K
|
| Email alert
Add to watchlist
plify-201 cell ongoing preclinical meeting eli-002 therapeutics response study
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
Published: 2024-04-04 (Crawled : 11:00) - biospace.com/
ACHL | $0.8145 1.53% -0.28% 180K
|
Manufacturing
|
| O: -16.22%
H: 0.99%
C: -7.89%
first melanoma update therapeutics advanced
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Published: 2024-04-03 (Crawled : 12:00) - globenewswire.com
CTMX | $1.76 -5.38% -5.38% 590K
|
Health Technology
|
| O: -0.47%
H: 2.35%
C: 0.94%
probody candidate t-cell collaboration therapeutics
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
Published: 2024-03-28 (Crawled : 13:00) - globenewswire.com
MBIO | $0.384 10.92% 7.18% 270K
|
Health Technology
|
| O: 7.14%
H: 1.9%
C: -0.95%
FBIO | $1.77 0.57% 1.68% 250K
|
Health Technology
|
| O: -0.46%
H: 0.46%
C: -7.41%
t-cell expansion vision therapy platform
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Published: 2024-03-18 (Crawled : 12:00) - globenewswire.com
CTMX | $1.76 -5.38% -5.38% 590K
|
Health Technology
|
| O: 0.97%
H: 0.48%
C: -3.35%
probody collaboration therapeutics milestone
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
Published: 2024-03-18 (Crawled : 12:30) - prnewswire.com
CTXR | $0.8162 8.86% 9.33% 640K
|
Health Technology
|
| O: -2.23%
H: 11.11%
C: 0.03%
fda t-cell resubmission treatment pharmaceuticals
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas - March 18, 2024
Published: 2024-03-18 (Crawled : 16:00) - biospace.com/
CTMX | $1.76 -5.38% -5.38% 590K
|
Health Technology
|
| O: 0.97%
H: 0.48%
C: -3.35%
probody t-cell collaboration therapeutics milestone
City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial
Published: 2024-03-07 (Crawled : 12:30) - biospace.com/
FNCTF | News | $11.0354 -0.83% -20.84% 34K
|
Communications
|
| O: 0.79%
H: 0.78%
C: 0.78%
MBIO | $0.384 10.92% 7.18% 270K
|
Health Technology
|
| O: 8.33%
H: 4.2%
C: -2.8%
FBIO | $1.77 0.57% 1.68% 250K
|
Health Technology
|
| O: 2.93%
H: 0.0%
C: -9.21%
tumors cell city trial therapy
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
Published: 2024-03-07 (Crawled : 12:30) - globenewswire.com
MBIO | $0.384 10.92% 7.18% 270K
|
Health Technology
|
| O: 8.33%
H: 4.2%
C: -2.8%
FBIO | $1.77 0.57% 1.68% 250K
|
Health Technology
|
| O: 2.93%
H: 0.0%
C: -9.21%
mb-101 publication trial
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
Published: 2024-03-06 (Crawled : 15:30) - biospace.com/
MRUS | $41.05 1.84% 1.71% 410K
|
Health Technology
|
| O: 0.06%
H: 1.66%
C: -2.56%
GILD | $66.93 -0.57% -0.55% 3.8M
|
Health Technology
|
| O: -0.15%
H: 0.6%
C: -0.34%
t-cell collaboration
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
Published: 2024-03-05 (Crawled : 13:00) - globenewswire.com
NXTC | $1.51 -7.93% -8.61% 120K
|
Health Technology
|
| O: -5.76%
H: 7.22%
C: 5.56%
cell preclinical
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-03-05 (Crawled : 22:00) - globenewswire.com
CRBU | $3.91 -2.49% -2.3% 1.7M
|
Health Technology
|
| O: 1.63%
H: 0.54%
C: -0.67%
cb-012 association cancer cell research preclinical meeting car-t
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial
Published: 2024-02-29 (Crawled : 13:00) - globenewswire.com
VIRX | $0.9362 30.97% 21.62% 190K
|
Manufacturing
|
| O: 0.0%
H: 3.37%
C: -8.43%
t-cell trial therapeutics
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference
Published: 2024-02-29 (Crawled : 15:00) - biospace.com/
COYA | $8.24 0.86% 0.37% 75K
|
|
| O: 0.0%
H: 1.1%
C: -5.86%
conference cell dementia system therapeutics
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology
Published: 2024-02-14 (Crawled : 13:00) - globenewswire.com
INAB | $1.0 2.01% 3.89% 170K
|
|
| O: 0.83%
H: 5.79%
C: -7.44%
publication cell immunology therapy glioblastoma
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
INVO | $1.82 139.47% 56.82% 220M
|
Health Technology
SINT | $0.0373 62.88% 37.26% 460M
|
Health Technology
WISA 4 | $9.25 51.64% 34.27% 64M
|
Electronic Technology
EDBL | News | $6.66 46.37% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 600K
|
Manufacturing
TCON | $2.29 33.92% 26.61% 1.8M
|
Health Technology
TIRX | $0.4848 7.49% 24.58% 5.9M
|
SRFM 4 | $0.3859 -12.3% 23.84% 660K
|
n/a
KZIA | $0.3442 18.28% 23.42% 290K
|
Health Technology
VNDA | News | $5.24 29.38% 22.56% 24M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.